Effects of combined probucol-colestipol treatment for familial hypercholesterolemia and coronary artery disease
- 27 June 1986
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 57 (16), H43-H48
- https://doi.org/10.1016/0002-9149(86)90437-6
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- The LDL receptor locus in familial hypercholesterolemia: Multiple mutations disrupt transport and processing of a membrane receptorCell, 1983
- Familial Type II Hyperlipoproteinemia with Coronary Heart DiseaseChest, 1981
- Normalization of Low-Density-Lipoprotein Levels in Heterozygous Familial Hypercholesterolemia with a Combined Drug RegimenNew England Journal of Medicine, 1981
- Use of combined diet and colestipol in long-term (7--7 1/2 years) treatment of patients with type II hyperlipoproteinemia.Circulation, 1979
- The Low-Density Lipoprotein Pathway and its Relation to AtherosclerosisAnnual Review of Biochemistry, 1977
- Familial Hypercholesterolemia: A Genetic Defect in the Low-Density Lipoprotein ReceptorNew England Journal of Medicine, 1976
- Mode of action of a new hypocholesteraemic drug (DH-581) in familial hypercholesteraemiaAtherosclerosis, 1972
- Hypocholesterolesmic Effect of 4,4′-(Isopropylidenedithio)-Bis(2,6-di-t-Butylphenol) (Probucol)The American Journal of Clinical Nutrition, 1970
- Effects of colestipol (U-26,597A), a new bile acid sequestrant, on serum lipids in experimental animals and manAtherosclerosis, 1970